Lynn Seely, Md
Chief Executive Officer
immunology
Myovant Science
Botswana
Biography
Dr. Seely is a director and the principal executive officer of Myovant Sciences Ltd., and President and Chief Executive Officer of its wholly-owned subsidiary, Myovant Sciences, Inc. At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the board of directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
Research Interest
Dr. Seely is a director and the principal executive officer of Myovant Sciences Ltd., and President and Chief Executive Officer of its wholly-owned subsidiary, Myovant Sciences, Inc. At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the board of directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
